Screener
Sabra Healthcare SBRA Proceeds From Repayments Of Lines Of Credit
Proceeds From Repayments Of Lines Of Credit at other companies
Other financials
Where this comes from
Reported directly by Sabra Healthcare in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromRepaymentsOfLinesOfCredit.
The source filing: Sabra Healthcare’s 10-Q, filed April 29, 2026.
- Filed
- Apr 29, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001492298-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Insurance proceeds | 107 | — |
| Net cash used in investing activities | (105,090) | (16,444) |
| Cash flows from financing activities: | ||
| Net borrowings from (repayments of) revolving credit facility | 137,800 | (23,881) |
| Principal payments on secured debt | (531) | (517) |
| Payments of deferred financing costs | (92) | (80) |
| Contributions from noncontrolling interests | 4 | — |
| Payment of contingent consideration | (1,178) | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Sabra Healthcare's proceeds from repayments of lines of credit?
- Sabra Healthcare (SBRA) reported proceeds from repayments of lines of credit of $137.8M in Q1 2026.
- How has Sabra Healthcare's proceeds from repayments of lines of credit changed year-over-year?
- Sabra Healthcare's proceeds from repayments of lines of credit increased by 677.0% year-over-year, from -$23.88M to $137.8M.
- What does proceeds from repayments of lines of credit mean?
- Cash inflows resulting from the repayment of principal amounts on lines of credit or revolving credit facilities extended to third parties. This reflects the company's role as a lender or the recovery of capital previously deployed through credit arrangements. It indicates the liquidity status of the company's credit-based investments.
Ask your AI about Sabra Healthcare's proceeds from repayments of lines of credit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude